Griet Vanpoucke
Directeur/Membre du Conseil chez Orionis Biosciences, Inc.
Profil
Griet Vanpoucke is currently a Director at Orionis Biosciences, Inc., Aelin Therapeutics NV, Montis Biosciences BV, and Orionis Biosciences BV.
She previously worked as a Director of Research & Development at MyCartis NV and as a Director at Flamingo Therapeutics BV from 2020 to 2023.
She holds a doctorate degree from Ghent University.
Postes actifs de Griet Vanpoucke
| Sociétés | Poste | Début |
|---|---|---|
Orionis Biosciences, Inc.
 Orionis Biosciences, Inc. Packaged SoftwareTechnology Services Orionis Biosciences, Inc. engages in operation of an biotechnology company that specializes in drug discovery. It offers A-Kine biologics and Allo-Glue, a small molecule platform with applications to the reprogramming of disease states. The company was founded by Nikolai Kley and Jan Tavernier and is headquartered in Waltham, MA. | Directeur/Membre du Conseil | 01/01/2015 |
Montis Biosciences BV
 Montis Biosciences BV BiotechnologyHealth Technology Montis Biosciences BV engages in the development of immune-oncology therapeutics targetting the intersection between vascular dysfunction and immune suppression to treat solid tumors. It offers target screening and assay platform to discover novel targets modulating interactions between tumor endothelial cells and perivascular macrophages. The company was founded by Peter Carmeliet and Massimiliano Mazzone and is headquartered in Meise, Belgium. | Directeur/Membre du Conseil | - |
Orionis Biosciences BV
 Orionis Biosciences BV Pharmaceuticals: MajorHealth Technology Part of Orionis Biosciences, Inc., Orionis Biosciences BV operates as a drug discovery and Belgian development biotechnology company. The company is based in Ghent, Belgium. The company was founded in 2015. Nikolai Kley has been the CEO of the company since 2015. | Directeur/Membre du Conseil | 02/09/2015 |
Aelin Therapeutics NV
 Aelin Therapeutics NV Pharmaceuticals: MajorHealth Technology Aelin Therapeutics NV develops drugs for antibiotics and first-in-class therapeutics. The company is based in Leuven, Belgium. The Belgian company was founded in 2017. The CEO is Els Beirnaert. | Directeur/Membre du Conseil | 01/01/2018 |
Anciens postes connus de Griet Vanpoucke
| Sociétés | Poste | Fin |
|---|---|---|
Flamingo Therapeutics BV
 Flamingo Therapeutics BV Miscellaneous Commercial ServicesCommercial Services Flamingo Therapeutics BV is a Belgian company that specializes in developing RNA-targeted therapies for oncology. The company is based in Leuven, Belgium and was founded by Mike Garrett and Floor Stam. Flamingo is dedicated to delivering therapeutic benefit to patients living with cancer and believes that their programs and approach can successfully address large unmet medical needs where RNA-targeting can be effective. The company's clinical-stage pipeline focuses on targeting undruggable transcription factors and splice variants. The CEO is Stephane van Rooijen. | Directeur/Membre du Conseil | 01/03/2023 |
MyCartis NV
 MyCartis NV BiotechnologyHealth Technology MyCartis NV develops technologies for healthcare personalization needs. It offers Evalution, a multiplex analysis platform to develop protein and nucleic-acid based clinical biomarkers. The company provides disruptive solutions in the fields of clinical and translational research for various applications in the detection of proteins and nucleic acids, such as sandwich immunoassays, antibody assays, genotyping assays, and mutation analysis assays to customers and partners. It offers products for various disease areas, including cell signalling, cardiovascular, oncology, and preeclampsia. The company was founded by Koen Kas in August 2004 and is headquartered in Ghent, Belgium. | Directeur Technique/Scientifique/R&D | - |
Formation de Griet Vanpoucke
| Ghent University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
MyCartis NV
MyCartis NV BiotechnologyHealth Technology MyCartis NV develops technologies for healthcare personalization needs. It offers Evalution, a multiplex analysis platform to develop protein and nucleic-acid based clinical biomarkers. The company provides disruptive solutions in the fields of clinical and translational research for various applications in the detection of proteins and nucleic acids, such as sandwich immunoassays, antibody assays, genotyping assays, and mutation analysis assays to customers and partners. It offers products for various disease areas, including cell signalling, cardiovascular, oncology, and preeclampsia. The company was founded by Koen Kas in August 2004 and is headquartered in Ghent, Belgium. | Health Technology |
Orionis Biosciences, Inc.
Orionis Biosciences, Inc. Packaged SoftwareTechnology Services Orionis Biosciences, Inc. engages in operation of an biotechnology company that specializes in drug discovery. It offers A-Kine biologics and Allo-Glue, a small molecule platform with applications to the reprogramming of disease states. The company was founded by Nikolai Kley and Jan Tavernier and is headquartered in Waltham, MA. | Technology Services |
Montis Biosciences BV
Montis Biosciences BV BiotechnologyHealth Technology Montis Biosciences BV engages in the development of immune-oncology therapeutics targetting the intersection between vascular dysfunction and immune suppression to treat solid tumors. It offers target screening and assay platform to discover novel targets modulating interactions between tumor endothelial cells and perivascular macrophages. The company was founded by Peter Carmeliet and Massimiliano Mazzone and is headquartered in Meise, Belgium. | Health Technology |
Flamingo Therapeutics BV
Flamingo Therapeutics BV Miscellaneous Commercial ServicesCommercial Services Flamingo Therapeutics BV is a Belgian company that specializes in developing RNA-targeted therapies for oncology. The company is based in Leuven, Belgium and was founded by Mike Garrett and Floor Stam. Flamingo is dedicated to delivering therapeutic benefit to patients living with cancer and believes that their programs and approach can successfully address large unmet medical needs where RNA-targeting can be effective. The company's clinical-stage pipeline focuses on targeting undruggable transcription factors and splice variants. The CEO is Stephane van Rooijen. | Commercial Services |
Orionis Biosciences BV
Orionis Biosciences BV Pharmaceuticals: MajorHealth Technology Part of Orionis Biosciences, Inc., Orionis Biosciences BV operates as a drug discovery and Belgian development biotechnology company. The company is based in Ghent, Belgium. The company was founded in 2015. Nikolai Kley has been the CEO of the company since 2015. | Health Technology |
Aelin Therapeutics NV
Aelin Therapeutics NV Pharmaceuticals: MajorHealth Technology Aelin Therapeutics NV develops drugs for antibiotics and first-in-class therapeutics. The company is based in Leuven, Belgium. The Belgian company was founded in 2017. The CEO is Els Beirnaert. | Health Technology |